Bayer AG Presents Strategic Growth Through 2030

The company presented a robust portfolio based on five key therapeutic areas that will mark its growth through 2030. During the Pharma Media Day 2026, Bayer AG presented a strategic update that evidenced the consolidation of its pharmaceutical portfolio, considered the most robust in its history, along with a multimodal pipeline aimed at driving growth through 2030. The event allowed to detail the regulatory advances achieved in 2025, a year in which the company registered five regulatory approvals, new indications, and relevant clinical results, as well as the milestones planned for 2026 in key research areas. Corporate strategy: science, discipline, and growth. Stefan Oelrich, a member of the Bayer AG Board of Management and President of the Pharmaceuticals division, explained that the company's evolution is based on a strategy of scientific rigor and business focus. He noted that the observed results reflect a structural transformation, sustained by an innovative portfolio, a diversified pipeline, and an increasingly AI-driven operational model. He also highlighted that the organization projects to resume a sustained mid-single-digit growth from 2027, with the expectation of reaching a margin expansion close to 30% by 2030. Five therapeutic areas as engines of innovation. Bayer AG's strategy is structured around five priority therapeutic areas: cardiology, kidney disease, oncology, neurology, and women's health. Christine Roth, Executive Vice President and Head of Global Product and Commercialization Strategy, emphasized that the company aims to position itself as a leader in therapeutic innovation, prioritizing solutions that generate a direct impact on patients. She indicated that strategic decisions made in recent years have enabled the acceleration of new treatment development and strengthening of the response to unmet medical needs. Cardiology and kidney disease: response to a growing global burden. In the cardiovascular field, the company is developing therapies aimed at preventing stroke events through Factor XIa inhibition, with the goal of reducing clot formation without compromising normal coagulation. It was highlighted that approximately 12 million strokes are registered each year, 80% of which are ischemic, and that one in five patients experiences a second event within a five-year period. Similarly, in diseases like transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bayer introduced in Europe a therapy that stabilizes the TTR gene, aimed at a progressive pathology that affects around 400,000 people worldwide. In parallel, the development of treatments for chronic kidney disease and heart failure responds to a global burden exceeding 875 million people, with high mortality rates, particularly when both conditions coexist. Oncology and women's health: focus on quality of life. In oncology, the company is working on new generations of androgen receptor inhibitors for the treatment of metastatic hormone-sensitive prostate cancer, one of the most frequent tumors in men and responsible for nearly 400,000 deaths annually. On the other hand, in women's health, therapies are being developed for vasomotor symptoms associated with menopause, such as breast cancer, with the aim of improving quality of life, sleep, and well-being in a population that could reach 1.2 billion women by 2030. Innovative pipeline and advanced medicine. Christian Rommel, Executive Vice President and Global Head of Research and Development, highlighted that recent results validate the company's innovation strategy, with advances in precision medicine, cell and gene therapies, and molecular imaging. In this context, the collaboration with AskBio was highlighted, aimed at developing transformative gene therapies. Gustavo Pesquin, CEO of AskBio, explained that the integration of technological and operational capabilities will allow for progress in innovative treatments for rare and common diseases. Regenerative medicine and new therapeutic frontiers. In the field of regenerative medicine, cell therapies are being developed for diseases such as heart failure with reduced ejection fraction, which affects around 64 million people worldwide. Cell therapies are also being researched for Parkinson's disease, whose prevalence has doubled in recent decades, reaching approximately 12 million people globally. Seth Ettenberg, President and CEO of BlueRock Therapeutics, noted that this approach represents a new therapeutic pathway for diseases characterized by the irreversible loss of cells. In ophthalmology, the use of stem cells to treat photoreceptor diseases, which cause irreversible vision loss in more than 110,000 people in the United States alone, is being explored. Artificial intelligence and strategic alliances. The company highlighted the role of artificial intelligence as a cross-cutting element in research and development. Sai Jasti, Senior Vice President and Head of Data Science and AI, indicated that Bayer plans to increase R&D productivity by 40% by 2030 through the use of data platforms and advanced models. Partnerships with institutions such as Vanderbilt University Medical Center, FinnGen, and PRECISE, as well as the collaboration with the company Cradle, are part of a global ecosystem aimed at accelerating drug discovery. A strategy focused on global impact. Bayer AG's positioning is based on its mission to contribute to global health through the development of solutions that address the challenges of a growing and aging population. With a workforce of around 88,000 employees and R&D investment reaching 5.8 billion euros in 2025, the company reaffirmed its commitment to innovation, sustainability, and access to advanced treatments.